Q-omics provides the consensus-scored MTNR1A profile across patient tissues and cancer cell-line models. MTNR1A expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MTNR1A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MTNR1A RNA expression shows 13,086 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KICH, and TGCT as cancer lineages where MTNR1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTNR1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTNR1A survival associations across molecular data types. MTNR1A RNA expression shows survival associations in the most cancer types (13), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTNR1A RNA expression–survival associations across cancer types. High MTNR1A expression shows unfavorable associations in CESC, ACC, BLCA, LUSC and UCEC, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify BRCA as the clearest survival context for MTNR1A RNA expression.
This table summarizes MTNR1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTNR1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTNR1A shows lower tumor expression in KICH, KIRC, COAD and KIRP and higher tumor expression in LUAD and LUSC. The KICH box plot shows higher MTNR1A RNA expression in normal versus tumor tissue (log2 FC = −1.547, t-test p < 0.001).
This table shows molecular features associated with MTNR1A in patient tissues and cancer cell lines. In patient samples, MTNR1A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MTNR1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
